Sphingolipid metabolism plays an essential role in the functional integrity of the nervous system, immune activation, inflammatory response, cardiac and kidney functions. Alteration in the metabolism of sphingolipids links to a group of rare genetic diseases caused by a defect in lysosomal sphingolipid degradation. A majority of sphingolipids disorders, including lysosomal storage disorders, are associated with neurodegenerative processes, metabolic and proliferative disorders. However, the occurrence of cancer among patients with lysosomal storage disorders was never systematically examined, except for type 1 Gaucher disease, where risk of developing hematological malignancies was recognized.
Overall, bioactive sphingolipids play a crucial role in major aspects of cell signaling pathways, including autophagy-lysosomal signaling pathway, cell cycle, apoptosis, cell migration, endocytosis, and mitochondrial metabolism. Recently, sphingolipids are receiving increasing attention as contributors to cancer progression and responders to chemotherapy. It has been demonstrated that many types of tumors display dysregulation of sphingolipid metabolism. If so, understanding sphingolipid metabolism becomes important in the clinic for development of novel therapies and diagnostics of cancer.
This Research Topic focuses on functional disruption of sphingolipid metabolism in cancer pathology and a review of novel therapeutic agents targeting sphingolipid metabolism. Additionally, the topic includes prediction of cancer risk and cancer therapy for patients with sphingolipid disorders.
We welcome the submission of original research, clinical trials, clinical cases and reviews. We also encourage undergraduate and graduate students and postdoctoral trainees to write reviews with mentors, focusing on, but not limited to the following subtopics:
1. Sphingolipids metabolism and cancer progression.
2. Targeting sphingolipid metabolism as an approach for cancer therapy.
3. Small-molecules and inhibitors that target sphingolipid metabolism as a therapy for brain cancer.
4. Sphingolipid metabolism disorders and cancer.
Note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Sphingolipid metabolism plays an essential role in the functional integrity of the nervous system, immune activation, inflammatory response, cardiac and kidney functions. Alteration in the metabolism of sphingolipids links to a group of rare genetic diseases caused by a defect in lysosomal sphingolipid degradation. A majority of sphingolipids disorders, including lysosomal storage disorders, are associated with neurodegenerative processes, metabolic and proliferative disorders. However, the occurrence of cancer among patients with lysosomal storage disorders was never systematically examined, except for type 1 Gaucher disease, where risk of developing hematological malignancies was recognized.
Overall, bioactive sphingolipids play a crucial role in major aspects of cell signaling pathways, including autophagy-lysosomal signaling pathway, cell cycle, apoptosis, cell migration, endocytosis, and mitochondrial metabolism. Recently, sphingolipids are receiving increasing attention as contributors to cancer progression and responders to chemotherapy. It has been demonstrated that many types of tumors display dysregulation of sphingolipid metabolism. If so, understanding sphingolipid metabolism becomes important in the clinic for development of novel therapies and diagnostics of cancer.
This Research Topic focuses on functional disruption of sphingolipid metabolism in cancer pathology and a review of novel therapeutic agents targeting sphingolipid metabolism. Additionally, the topic includes prediction of cancer risk and cancer therapy for patients with sphingolipid disorders.
We welcome the submission of original research, clinical trials, clinical cases and reviews. We also encourage undergraduate and graduate students and postdoctoral trainees to write reviews with mentors, focusing on, but not limited to the following subtopics:
1. Sphingolipids metabolism and cancer progression.
2. Targeting sphingolipid metabolism as an approach for cancer therapy.
3. Small-molecules and inhibitors that target sphingolipid metabolism as a therapy for brain cancer.
4. Sphingolipid metabolism disorders and cancer.
Note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
